In early November, we launched our VaxiRNA™ platform as a result of research performed by our Alnylam Biotherapeutics team. VaxiRNA uses siRNA to silence specific genes that limit or prevent effective growth of viruses in vaccine manufacturing systems, including those in cell culture and also in chicken eggs.
View Illustration (2.28MB PDF) Read our press release
This part of our website contains archived information which should not be considered current and may no longer be accurate.
